| Literature DB >> 27459192 |
Miao He1,2, Zhuan Bian1.
Abstract
BACKGROUND: Grainyhead-like-3 (GRHL3) was recently identified as the second gene that, when mutated, can leads to Van der Woude syndrome, which is characterized by orofacial clefts (OFC) and lower lip pits. In addition, a missense variant (rs41268753) in GRHL3 confers risk for non-syndromic cleft palate cases of European ancestry. Together with interferon regulatory factor 6 (IRF6), GRHL3 may be associated with the risk of NSOFC which awaits for being verified across different ethnic populations.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27459192 PMCID: PMC4961390 DOI: 10.1371/journal.pone.0159940
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
General information for genotyped SNPs.
| SNP ID | Gene | Chr. | Posotion | Region | SNPs | Function | Amino Acid Changes | MAF | HWE |
|---|---|---|---|---|---|---|---|---|---|
| rs2486668 | 1 | 24658063 | exon 2 | C>G | missense | Asp | 0.22 | 0.996 | |
| rs545809 | 1 | 24690764 | exon 16 | T>A | missense | Met | 0.42 | 0.997 |
aMAF, minor allele frequency; CHB, Chinese Han Chinese in Beijing, China.
bHardy-Weinberg equilibrium among controls.
cAsp, aspartic acid.
dGlu, glutamic acid.
e Met, methionine.
f Lys, lysine.
Genotypic and allelic distributions of rs2486668 in NSOFC cases and controls.
| rs2486668 | Controls (n = 376,%) | All cleft cases (n = 768,%) | CL/P (n = 471, %) | CLP (n = 257, %) | CLO (n = 214, %) | CPO (n = 297, %) |
|---|---|---|---|---|---|---|
| CC | 235(62.5) | 480(62.5) | 290(61.6) | 161(62.6) | 129(60.3) | 190(64.0) |
| CG | 125(33.2) | 255(33.2) | 157(33.3) | 85(33.1) | 72(33.6) | 98(33.0) |
| GG | 16(4.3) | 33(4.3) | 24(5.1) | 11(4.3) | 13(6.1) | 9(3.0) |
| Pa | - | 0.994 | 0.8428 | 0.999 | 0.5963 | 0.694 |
| CG vs. CC | - | 1.00(0.77, 1.30) | 1.02(0.80, 1.30) | 0.99(0.72, 1.38) | 1.05(0.71, 1.55) | 0.97(0.66, 1.41) |
| GG vs. CC | - | 1.01(0.54, 1.87) | 1.22(0.70,1.80) | 1.00(0.48, 2.10) | 1.48(0.64, 3.41) | 0.70(0.29, 1.68) |
| CG/GG vs. CC | - | 1.00(0.78, 1.29) | 1.04(0.82,1.32) | 0.99(0.73, 1.36) | 1.09(0.76, 1.60) | 0.93(0.65, 1.35) |
| CG/CC vs. GG | - | 0.99(0.54, 1.82) | 0.83(0.48, 1.41) | 0.99(0.48, 2.06) | 0.69(0.30, 1.57) | 1.42(0.60, 3.39) |
| C | 0.79 | 0.79 | 0.78 | 0.79 | 0.77 | 0.8 |
| G | 0.21 | 0.21 | 0.22 | 0.21 | 0.23 | 0.2 |
| P | - | 1 | 0.8592 | 0.9538 | 0.8989 | 0.8431 |
CL/P, cleft lip with or without cleft palate; CLP, cleft lip with palate; CLO, cleft lip only; CPO, cleft palate only; OR, odds ratio; CI, confidence interval.
aComparison of genotype and allele frequencies among cases and controls were performed by two-sided Chi-square test.
Genotypic and allelic distributions of rs545809 in NSOFC cases and controls.
| rs545809 | Controls (n = 376,%) | All cleft cases (n = 768,%) | CL/P (n = 471, %) | CLP (n = 257, %) | CLO (n = 214, %) | CPO (n = 297, %) |
|---|---|---|---|---|---|---|
| TT | 139(37.0) | 284(37.0) | 157(33.3) | 94(36.6) | 63(29.4) | 127(42.8) |
| AT | 180(47.9) | 368(47.9) | 235(50.0) | 117(45.5) | 118(55.1) | 133(44.8) |
| AA | 57(15.2) | 116(15.1) | 79(16.8) | 46(17.9) | 33(15.4) | 37(12.5) |
| P | - | 0.9997 | 0.7195 | 0.7782 | 0.4741 | 0.1575 |
| AT vs. TT | - | 1.00(0.76, 1.31) | 1.16(0.90, 1.49) | 0.96(0.69, 1.35) | 1.45(0.96, 2.18) | 0.81(0.55, 1.20) |
| AA vs. TT | - | 1.00(0.68, 1.45) | 1.23(0.87, 1.73) | 1.19(0.77, 1.86) | 1.28(0.74, 2.21) | 0.71(0.41, 1.24) |
| AT/AA vs. TT | - | 1.00(0.77, 1.29) | 1.17(0.92, 1.49) | 1.02(0.74, 1.40) | 1.41(0.95, 2.07) | 0.79(0.54, 1.14) |
| AT/TT vs. AA | - | 1.00(0.71, 1.42) | 0.89(0.65, 1.21) | 0.82(0.55, 1.22) | 0.98(0.60, 1.60) | 1.26(0.76, 2.08) |
| T | 0.61 | 0.61 | 0.58 | 0.59 | 0.57 | 0.65 |
| A | 0.39 | 0.39 | 0.42 | 0.41 | 0.43 | 0.35 |
| P | - | 1 | 0.3772 | 0.5578 | 0.4725 | 0.0769 |
CL/P, cleft lip with or without cleft palate; CLP, cleft lip with palate; CLO, cleft lip only; CPO, cleft palate only; OR, odds ratio; CI, confidence interval.
aComparison of genotype and allele frequencies among cases and controls were performed by two-sided Chi-square test.